Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

233
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
233
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

1.4K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.4K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

642
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
642

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Pragmatic SMART Study of Medication and CBT Sequencing in Pediatric Anxiety Disorders: A Randomized Clinical Trial.

The American journal of psychiatry·2026
Same author

Identifying the Aggression Impulsive/Reactive (AIR) Profile in Youth With Behavioral Challenges.

JAACAP open·2026
Same author

Diagnosis and Medication Treatment of Schizophrenia in Adolescents.

Drugs·2026
Same author

Data Diversity vs. Model Complexity in the Prediction of Pediatric Bipolar Disorder: Evidence from Academic and Community Clinical Samples.

medRxiv : the preprint server for health sciences·2026
Same author

Latent profiles of mood: Toward an empirical definition of mixed mood in youth.

Journal of affective disorders·2026
Same author

Editors' Best of 2025.

JAACAP open·2026

Related Experiment Video

Updated: May 3, 2026

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.7K

Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS).

Robert L Findling1, Steven Dinh

  • 1Division of Child and Adolescent Psychiatry, The Johns Hopkins Hospital, 1800 Orleans Street, Bloomberg Children's Center 12344-A, Baltimore, MD, 21287, USA, rfindli1@jhmi.edu.

CNS Drugs
|February 18, 2014
PubMed
Summary

The methylphenidate transdermal system (MTS) offers an effective and safe treatment for attention-deficit hyperactivity disorder (ADHD) in children and adolescents. This patch provides sustained symptom control and improved quality of life with manageable side effects.

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:43

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

220

Related Experiment Videos

Last Updated: May 3, 2026

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.7K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

13.0K
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:43

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

220

Area of Science:

  • Pharmacology
  • Neuroscience
  • Pediatrics

Background:

  • Transdermal technology is an established drug delivery method, with over 20 medications approved in the US.
  • Attention-deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder in children and adolescents.
  • Methylphenidate is a common pharmacotherapy for ADHD.

Purpose of the Study:

  • To review clinical research on the efficacy and safety of the methylphenidate transdermal system (MTS) for ADHD treatment in pediatric populations.
  • To evaluate the pharmacokinetic profile and clinical outcomes associated with MTS application.
  • To compare MTS with placebo and other methylphenidate formulations.

Main Methods:

  • Systematic review of clinical trials identified via PubMed searches using 'methylphenidate transdermal system'.
  • Inclusion of studies evaluating safety and efficacy in children and adolescents.
  • Assessment of ADHD symptoms using ADHD Rating Scale, Version IV, and various rating scales.
  • Pharmacokinetic analysis of serum methylphenidate levels and elimination half-life.

Main Results:

  • MTS demonstrated statistically significant improvements in ADHD symptoms from 2 hours post-application, with benefits lasting up to 12 hours.
  • Adverse events were comparable to other methylphenidate formulations, with mild to moderate skin reactions in <1% of users.
  • Significant improvements were noted in health-related quality of life and medication satisfaction compared to placebo and oral extended-release methylphenidate.

Conclusions:

  • The methylphenidate transdermal system (MTS) is a safe and effective option for managing ADHD in children and adolescents.
  • MTS provides consistent therapeutic drug levels and sustained symptom control.
  • Transdermal delivery offers a viable alternative for methylphenidate administration, enhancing patient compliance and quality of life.